Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.74 |
| ▸ | DDB1 | Q16531 | 4/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.58 |
| ▸ | BRD4 | O60885 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16120061 | 0.88 | CRBN (0.72) | CRBNDDB1IKZF3BRD4 | |
| SCHEMBL5496321 | 0.88 | CRBN (0.76) | CRBNDDB1IKZF3BRD4 | |
| SCHEMBL4778758 | 0.87 | CRBN (0.66) | CRBNDDB1IKZF3BRD4 | |
| SCHEMBL20811963 | 0.86 | CRBN (0.74) | CRBNDDB1ALDH1A1IKZF3BRD4 | |
| SCHEMBL4781353 | 0.86 | CRBN (0.77) | CRBNDDB1ALDH1A1IKZF3BRD4 | |
| SCHEMBL19359322 | 0.85 | CRBN (0.69) | CRBNDDB1IKZF3BRD4 | |
| SCHEMBL23267776 | 0.85 | CRBN (0.72) | CRBNDDB1IKZF3BRD4 | |
| SCHEMBL20812183 | 0.85 | CRBN (0.72) | CRBNDDB1IKZF3BRD4 | |
| SCHEMBL17169740 | 0.85 | CRBN (0.72) | CRBNDDB1IKZF3BRD4 | |
| SCHEMBL20811955 | 0.85 | CRBN (0.72) | CRBNDDB1ALDH1A1IKZF3BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017081701-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF THALIDOMIDE | NATCO PHARMA LTD (IN) | 2017-05-18 | — | — | WO | disclosed |
| US-20120142734-A1 | METHODS FOR TREATING TUMORS WITH THALIDOMIDE | THE CHILDREN'S MEDICAL CENTER CORPORATION | 2012-06-07 | — | — | US | disclosed |
| US-8143283-B1 | Methods for treating blood-born tumors with thalidomide | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-7723361-B2 | Methods for inhibiting undesired angiogenesis in patients having tumors with thalidomide | CELGENE CORPORATION (US) | 2010-05-25 | — | — | US | disclosed |
| US-20080167272-A1 | Thalidomide metabolites and methods of use | AUCKLAND UNISERVICES LIMITED (NZ) | 2008-07-10 | — | — | US | disclosed |
| US-20080167272-A1 | Thalidomide metabolites and methods of use | AUCKLAND UNISERVICES LIMITED (NZ) | 2008-07-10 | — | — | US | disclosed |
| US-20080167272-A1 | Thalidomide metabolites and methods of use | AUCKLAND UNISERVICES LIMITED (NZ) | 2008-07-10 | — | — | US | disclosed |
| WO-2008007979-A1 | (2,6-DIOXO-3-PIPERINYL)AMIDOBENZOIC IMMUNOMODULATORY AND ANTI-CANCER DERIVATIVES | AUCKLAND UNISERVICES LIMITED (NZ) | 2008-01-17 | — | — | WO | disclosed |
| US-20070105903-A1 | Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs | CELGENE CORPORATION | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167272-A1 | Thalidomide metabolites and methods of use | TPMT, MALT1, FAP | CRBN 166/4885DDB1 653/4885ALDH1A1 202/4885 |
| US-20070105903-A1 | Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs | VEGFA, FLT4, FLT1 | CRBN 138/4885DDB1 499/4885ALDH1A1 2713/4885 |
| US-20120142734-A1 | METHODS FOR TREATING TUMORS WITH THALIDOMIDE | PGF, FLT4, HIF1AN | CRBN 138/4885DDB1 1184/4885ALDH1A1 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.